Lion Point Capital LP 13D and 13G filings for Marinus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 4:18 pm Sale | 2023-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS | Lion Point Capital LP | 2,134,337 3.900% | -2,645,311 (-55.35%) | Filing |
| 2023-02-14 4:15 pm Purchase | 2022-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS | Lion Point Capital LP | 4,779,648 9.900% | 1,150,026 (+31.68%) | Filing |
| 2022-02-14 4:31 pm Sale | 2021-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS | Lion Point Capital LP | 3,629,622 9.870% | -939,312 (-20.56%) | Filing |
| 2021-02-12 3:55 pm Purchase | 2020-12-31 | 13G | Marinus Pharmaceuticals, Inc. MRNS | Lion Point Capital LP | 4,568,934 12.200% | 2,975,249 (+186.69%) | Filing |